Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse

Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 1

Abstract

The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reuptake inhibitor is expected to partially substitute for cocaine, thus decreasing cocaine self-administration and minimizing the craving for cocaine. This type of indirect agonist therapy has been highly effective for treating smoking addiction (nicotine replacement therapy) and heroin addiction (methadone). To be an effective pharmacotherapy for cocaine addiction, the potential drug must be safe, long-acting, and have minimal abuse potential. We have developed several 3-phenyltropane analogs that are potent dopamine uptake inhibitors, and some are selective for the dopamine transporter relative to the serotonin and norepinephrine transporters. In animal studies, these compounds substitute for cocaine, reduce the intake of cocaine in rats and rhesus monkeys trained to self-administer cocaine, and have demonstrated a slow onset and long duration of action and lack of sensitization. The 3-phenyltropane analogs were also tested in a rhesus monkey self-administration model to define their abuse potential relative to cocaine. Based on these studies, 3β-(4-chlorophenyl)-2β-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (RTI-336) has been selected for preclinical development.

Authors and Affiliations

F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, Michael J. Kuhar

Keywords

Related Articles

Characterization of the distribution, polymorphism, and stability of nimodipine in its solid dispersions in polyethylene glycol by micro-Raman spectroscopy and powder x-ray diffraction

In the present study, a series of solid dispersions of the drug nimodipine using polyethylene glycol as carrier were prepared following the hot-melt method. Micro-Raman spectroscopy in conjunction with X-ray powder diffr...

Hyaluronidase-Sensitive Nanoparticle Templates for Triggered Release of HIV/AIDS Microbicide In Vitro

The online version of this article (doi:10.1208/s12248-013-9546-7) contains supplementary material, which is available to authorized users.

Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model

The online version of this article (doi:10.1208/s12248-015-9792-y) contains supplementary material, which is available to authorized users.

Estimation of capping incidence by indentation fracture tests

The purpose of this study was to predict the capping tendencies of pharmaceutical powders by creating indentation fracture on compacts. Three sets of binary mixtures containing different concentrations of each ingredient...

Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat

The objective of this research was to assess the effects of type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) on the pharmacokinetics of human IgG (hIgG), an antibody isotype, in Zucker diabetic fatty (ZDF) r...

Download PDF file
  • EP ID EP681655
  • DOI  10.1208/aapsj080124
  • Views 97
  • Downloads 0

How To Cite

F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, Michael J. Kuhar (2006). Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. The AAPS Journal, 8(1), -. https://europub.co.uk/articles/-A-681655